−0.85USD
−46.13 MUSD
68.21 KUSD
48.83 M
About InflaRx N.V.
Sector
Industry
CEO
Niels Christoph Riedemann
Website
Headquarters
Jena
Employees (FY)
66
Founded
2007
ISIN
NL0012661870
FIGI
BBG00HZ6PLC3
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
IFRX 1D Continuedtest
Just having some fun after a great ski trip to Breckenridge, Co for a couple of weeks. Let's get back into it.
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products
InflaRx recovering temporarily. IFRXWe are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistic
IFRX 1D Swing Editiontest
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products include IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in
InflaRx Announces Positive Data from Third Cohort of Phase IIa OIFRX: InflaRx N.V.
2021-10-27 07:30:00
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
$IFRX Strong Close!Keeping this one on watch most likely looking for the same volume coming in Monday. We closed very strong on Friday Which typically means we are looking for a strong move to the upside on Monday... Also looking for that SweetSpot break at $2.85 for Entry Confirmation.
$IFRX is gonna fall todayPupm&Dump trading strategy idea.
$IFRX is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $3,21;
stop-loss — $3,35;
take-profit — $2,93/MOC
Do not view
IFRX Technical Analysis 🧙InflaRx NV is a clinical-stage biopharmaceutical company that is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment
LONG // IFRX // US STOCKSTrade Safe! Don`t be greedy!
Take care and place small trades! If necessary, I will place more long trades at this asset!
In my opinion, this stock is at a good opportunity and has good potential for the stock price to go up!
$IFRX can rise in the next daysContextual immersion trading strategy idea.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the United States and Europe.
The share price rose after good earnings. I see some preconditions the share price will continue g
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of IFRX is 1.37 USD — it has decreased by 1.44% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange InflaRx N.V. stocks are traded under the ticker IFRX.
InflaRx N.V. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for InflaRx N.V. has a max estimate of 12.00 USD and a min estimate of 5.00 USD.
IFRX earnings for the last quarter are −0.14 USD whereas the estimation was −0.25 USD which accounts for 45.26% surprise. Estimated earnings for the next quarter are −0.20 USD. See more details about InflaRx N.V. earnings.
InflaRx N.V. revenue for the last quarter amounts to 64.27 K USD despite the estimated figure of 2.53 M USD. In the next quarter revenue is expected to reach 1.41 M USD.
Yes, you can track InflaRx N.V. financials in yearly and quarterly reports right on TradingView.
Like other stocks, IFRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade InflaRx N.V. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 66.00 employees. See our rating of the largest employees — is InflaRx N.V. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. InflaRx N.V. EBITDA is −62.03 M USD, and current EBITDA margin is −91.23 K%. See more stats in InflaRx N.V. financial statements.